DK0749478T3 - Gærstammer og modificerede albuminer - Google Patents

Gærstammer og modificerede albuminer

Info

Publication number
DK0749478T3
DK0749478T3 DK95909880T DK95909880T DK0749478T3 DK 0749478 T3 DK0749478 T3 DK 0749478T3 DK 95909880 T DK95909880 T DK 95909880T DK 95909880 T DK95909880 T DK 95909880T DK 0749478 T3 DK0749478 T3 DK 0749478T3
Authority
DK
Denmark
Prior art keywords
pct
albumin
yeast strains
yeast
yap3p
Prior art date
Application number
DK95909880T
Other languages
English (en)
Inventor
Sean Martin Kerry-Williams
Sarah Catherine Gilbert
Original Assignee
Delta Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delta Biotechnology Ltd filed Critical Delta Biotechnology Ltd
Application granted granted Critical
Publication of DK0749478T3 publication Critical patent/DK0749478T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/58—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
    • C12N9/60—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi from yeast

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK95909880T 1994-03-05 1995-03-01 Gærstammer og modificerede albuminer DK0749478T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9404270A GB9404270D0 (en) 1994-03-05 1994-03-05 Yeast strains and modified albumins
PCT/GB1995/000434 WO1995023857A1 (en) 1994-03-05 1995-03-01 Yeast strains and modified albumins

Publications (1)

Publication Number Publication Date
DK0749478T3 true DK0749478T3 (da) 2004-06-28

Family

ID=10751353

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95909880T DK0749478T3 (da) 1994-03-05 1995-03-01 Gærstammer og modificerede albuminer

Country Status (13)

Country Link
US (1) US5965386A (da)
EP (1) EP0749478B1 (da)
JP (1) JP3795073B2 (da)
KR (1) KR100372514B1 (da)
AT (1) ATE260338T1 (da)
AU (1) AU683728B2 (da)
CA (1) CA2183241C (da)
DE (1) DE69532603T2 (da)
DK (1) DK0749478T3 (da)
ES (1) ES2216007T3 (da)
GB (2) GB9404270D0 (da)
PT (1) PT749478E (da)
WO (1) WO1995023857A1 (da)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
JP3998717B2 (ja) * 1996-07-05 2007-10-31 ノボ ノルディスク アクティーゼルスカブ ポリペプチド類の製造方法
AU3255397A (en) * 1996-07-05 1998-02-02 Novo Nordisk A/S Method for the production of precursors of insulin, precursors of insulin analogues, and insulin like peptides
US6110703A (en) * 1996-07-05 2000-08-29 Novo Nordisk A/S Method for the production of polypeptides
US6274305B1 (en) 1996-12-19 2001-08-14 Tufts University Inhibiting proliferation of cancer cells
US6265186B1 (en) 1997-04-11 2001-07-24 Dsm N.V. Yeast cells comprising at least two copies of a desired gene integrated into the chromosomal genome at more than one non-ribosomal RNA encoding domain, particularly with Kluyveromyces
WO1999037758A2 (en) * 1998-01-27 1999-07-29 The Board Of Regents Of The University And Community College System Of Nevada On Behalf Of The University Of Nevada-Reno Expression of proteolytically-sensitive peptides
GB9902000D0 (en) 1999-01-30 1999-03-17 Delta Biotechnology Ltd Process
JP2003530838A (ja) 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
EP1317278B1 (en) * 2000-09-11 2009-11-11 Dana-Farber Cancer Institute, Inc. Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom
JP4276432B2 (ja) * 2000-12-22 2009-06-10 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド Ｍｕｃ１による細胞増殖調節方法
US20050054051A1 (en) * 2001-04-12 2005-03-10 Human Genome Sciences, Inc. Albumin fusion proteins
US7507413B2 (en) * 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
JP2003047471A (ja) * 2001-08-01 2003-02-18 Kirin Brewery Co Ltd 異種タンパク質の分泌生産に優れた改変酵母およびその酵母を用いた異種タンパク質の製造法
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
CA2484556A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
CA2471363C (en) 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
US7879365B2 (en) * 2002-02-07 2011-02-01 The Trustees Of Columbia University In The City Of New York Zinc salt compositions for the prevention of dermal and mucosal irritation
AU2003244516A1 (en) 2002-02-07 2003-09-02 Novozymes Delta Limited Hiv inhibiting proteins
WO2003091431A1 (fr) * 2002-04-26 2003-11-06 Kirin Beer Kabushiki Kaisha Methylotrophe produisant une chaine de sucre de type mammifere
KR100496758B1 (ko) * 2002-06-29 2005-06-22 한국생명공학연구원 한세눌라 폴리모르파 앱신 유전자 결손 변이주 및 이를이용한 재조합 단백질 생산 방법
US20080090770A1 (en) * 2003-04-11 2008-04-17 Belmares Michael P Modulation of Muc1 Mediated Signal Transduction
US8129506B2 (en) * 2003-10-24 2012-03-06 Genzyme Corporation Modulation of the interaction of MUC1 with MUC1 ligands
GB0329722D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Modified plasmid and use thereof
GB0329681D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Gene expression technique
CN1901931A (zh) * 2004-01-07 2007-01-24 特里梅里斯公司 HIV gp41 HR2－来源的合成肽,及其在抑制人类免疫缺陷性病毒传递的治疗中的用途
WO2005082458A1 (en) * 2004-02-23 2005-09-09 Genzyme Corporation Muc1 antagonist enhancement of death receptor ligand-induced apoptosis
EP1799713B1 (en) 2004-09-23 2014-11-05 VasGene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
DK2330200T3 (da) 2004-12-23 2017-07-24 Albumedix As Gene expression technique
KR20140077946A (ko) 2005-10-13 2014-06-24 휴먼 게놈 사이언시즈, 인코포레이티드 자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
EP1989220B1 (en) 2006-02-02 2011-12-14 Trimeris, Inc. Hiv fusion inhibitor peptides with improved biological properties
CA2658654A1 (en) 2006-07-24 2008-01-31 Biorexis Pharmaceutical Corporation Exendin fusion proteins
JP5256199B2 (ja) 2006-08-07 2013-08-07 テヴァ バイオファーマシューティカルズ ユーエスエー，インコーポレーティッド アルブミン−インスリン融合タンパク質
EP2069396B1 (en) 2006-09-08 2015-10-21 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
US7871784B2 (en) * 2007-02-02 2011-01-18 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by MUC1 and BH3-containing proapoptotic proteins
US7972870B2 (en) 2007-02-02 2011-07-05 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3
US20090068243A1 (en) * 2007-04-03 2009-03-12 Brian Bray Novel formulations for delivery of antiviral peptide therapeutics
EP2604623A3 (en) 2007-08-08 2013-10-02 Novozymes Biopharma DK A/S Transferrin variants and conjugates
CA2700354A1 (en) * 2007-09-25 2009-04-02 Trimeris, Inc. Novel methods of synthesis for therapeutic antiviral peptides
WO2010089385A1 (en) 2009-02-06 2010-08-12 Novozymes Biopharma Dk A/S Purification process
EP3243835B1 (en) 2009-02-11 2024-04-10 Albumedix Ltd Albumin variants and conjugates
GB2488077A (en) * 2009-10-30 2012-08-15 Novozymes Biopharma Dk As Albumin variants
US8815541B2 (en) 2009-11-25 2014-08-26 Novo Nordisk A/S Method for making polypeptides
WO2011103076A1 (en) 2010-02-16 2011-08-25 Medlmmune, Llc Hsa-related compositions and methods of use
CN102812119B (zh) * 2010-03-26 2015-05-20 朝日集团控股株式会社 酵母培养方法
JP5969458B2 (ja) 2010-04-09 2016-08-17 アルブミディクス アクティーゼルスカブ アルブミン誘導体及び変異体
US9045564B2 (en) 2011-02-15 2015-06-02 Medimmune, Llc HSA-related compositions and methods of use
CA2826683A1 (en) * 2011-02-15 2012-08-23 Medimmune, Llc Hsa-related compositions and methods of use
AU2012222833B2 (en) 2011-03-03 2017-03-16 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
CA2830660A1 (en) 2011-05-05 2012-11-08 Novozymes Biopharma Dk A/S Albumin variants
US20140315817A1 (en) 2011-11-18 2014-10-23 Eleven Biotherapeutics, Inc. Variant serum albumin with improved half-life and other properties
MX2014010278A (es) 2012-03-16 2015-03-05 Novozymes Biopharma Dk As Variantes de albumina.
JP6498601B2 (ja) 2012-07-13 2019-04-10 ザイムワークス，インコーポレイテッド 多価ヘテロ多量体足場設計および構築物
CA2890766A1 (en) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Albumin variants
CA2903739A1 (en) * 2013-03-06 2014-09-12 Glaxosmithkline Llc Host cells and methods of use
WO2014165093A2 (en) 2013-03-13 2014-10-09 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
WO2015001460A2 (en) * 2013-07-01 2015-01-08 Biocon Limited Signal sequence for protein expression in pichia pastoris
AU2016308504A1 (en) 2015-08-20 2018-01-18 Albumedix Ltd. Albumin variants and conjugates
KR20210111245A (ko) 2018-10-29 2021-09-10 스핀 테라퓨틱스, 엘엘씨 알파-1-항트립신 장애들을 위한 조성물들 및 방법들
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent
CN114957448B (zh) * 2022-06-08 2023-08-25 中国农业科学院生物技术研究所 一种高效表达α-乳白蛋白的酵母菌株和α-乳白蛋白及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01240191A (ja) * 1988-02-16 1989-09-25 Green Cross Corp:The 酵母で機能する新規シグナルペプチドおよびこれを用いた異種蛋白質の分泌発現
ATE157703T1 (de) * 1991-12-16 1997-09-15 Ciba Geigy Ag Endoplasmatisches retikulum-ständige rekombinante dibasische endoprotease und deren verwendungen
US5440018A (en) * 1992-05-20 1995-08-08 The Green Cross Corporation Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same

Also Published As

Publication number Publication date
CA2183241C (en) 2002-05-21
JPH09509581A (ja) 1997-09-30
CA2183241A1 (en) 1995-09-08
US5965386A (en) 1999-10-12
DE69532603D1 (de) 2004-04-01
AU683728B2 (en) 1997-11-20
PT749478E (pt) 2004-07-30
GB9616724D0 (en) 1996-09-25
KR100372514B1 (ko) 2004-04-30
JP3795073B2 (ja) 2006-07-12
WO1995023857A1 (en) 1995-09-08
DE69532603T2 (de) 2005-01-05
GB2301365B (en) 1997-07-30
EP0749478B1 (en) 2004-02-25
ATE260338T1 (de) 2004-03-15
GB2301365A (en) 1996-12-04
ES2216007T3 (es) 2004-10-16
EP0749478A1 (en) 1996-12-27
AU1818395A (en) 1995-09-18
GB9404270D0 (en) 1994-04-20

Similar Documents

Publication Publication Date Title
DK0749478T3 (da) Gærstammer og modificerede albuminer
WO1996017924A3 (en) Novel hedgehog-derived polypeptides
DK0423302T3 (da) Anvendelse af hidtil ukendte DNA-fragmenter som kodende sekvens for et signalpeptid til sekretion af modne proteiner i rekombinant gær, ekspressionskassetter, transformeret gær og tilsvarende fremgangsmåde til fremstilling af proteiner
GB2197324B (en) Process for the production of a polypeptide
ES2103366T3 (es) Hidrolizado proteico de guisante, metodo para su produccion y su utilizacion.
CA2189657A1 (fr) Fractions polypeptidiques solubles de la proteine lag-3; procede de production; composition therapeutique; anticorps anti-idiotype
ATE112687T1 (de) Mutanten des hiv-1 hüllproteins mit fehlenden hypervariabelen domänen.
DE59101889D1 (de) Variante cd44-oberflächenproteine, diese kodierende dna-sequenzen, antikörper gegen diese proteine sowie ihre verwendung in der diagnostik und therapie.
DE69431601T2 (de) Neue verwendung von dexmedetomidin
ATE183397T1 (de) Behandlung präkanzeröser läsionen durch muramylpeptide
DK0901526T3 (da) Cortistatin: neuropeptider, sammensætninger og metoder
DE69030920T2 (de) Verfahren zur herstellung von pai-2
DK41289A (da) Proteolytisk enzym, der er specifikt for human immundefektvirus og en fremgangsmaade til dets syntese og renaturering
DK0547200T3 (da) Rekombinante antistoffer på overfladen af E. coli
ATE371027T1 (de) Expressions- und sekretionsvektor für menschliches interferon alpha und verfahren zur herstellung von interferon alpha durch anwendung desselben
DE69431603T2 (de) Oligopeptide hergeleitet von fragmenten des c-reaktiven proteins
DE58909261D1 (de) Ancrod-proteine, ihre herstellung und verwendung.
NO961995D0 (no) Anvendelse av IGF-BP for renaturering av IGF
DE59611353D1 (de) Transketolase-verwandtes protein
DE59407666D1 (de) VERFAHREN ZUR HERSTELLUNG VON 8-g(a),12-OXIDO-13,14,15,16-TETRANORLABDAN
AU3476895A (en) Novel method for producing citric acid
ES2155768A1 (es) Caracterizacion y clonacion de la heteroglobina: una proteina de hamstac sirio que une inmunoglobulinas e humanas